Skip to main content
All lobbying filings

SAREPTA THERAPEUTICS, INC.

Lobbying for SAREPTA THERAPEUTICS, INC.

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2026 · California · House · Senate · $270,000.00 expenses · posted Apr 20, 2026

Official filing document

 Lobbying activity 2
Health Issues

Duchenne Muscular Dystrophy and Rare Disease Patient Access to Treatments Newborn Screening for Rare Diseases

Science/Technology

Scientific Innovation in Healthcare Gene Therapies Artificial Intelligence and Data Governance

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem